JP2009536522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536522A5 JP2009536522A5 JP2009509467A JP2009509467A JP2009536522A5 JP 2009536522 A5 JP2009536522 A5 JP 2009536522A5 JP 2009509467 A JP2009509467 A JP 2009509467A JP 2009509467 A JP2009509467 A JP 2009509467A JP 2009536522 A5 JP2009536522 A5 JP 2009536522A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- polypeptide
- amino acid
- cell
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 101150013553 CD40 gene Proteins 0.000 claims 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 6
- 230000003042 antagnostic effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 229940122551 CD40 antagonist Drugs 0.000 claims 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79881906P | 2006-05-09 | 2006-05-09 | |
| EP06076028A EP1854810A1 (en) | 2006-05-09 | 2006-05-09 | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| US60/798,819 | 2006-05-09 | ||
| EP06076028.7 | 2006-05-09 | ||
| PCT/NL2007/050202 WO2007129895A2 (en) | 2006-05-09 | 2007-05-09 | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536522A JP2009536522A (ja) | 2009-10-15 |
| JP2009536522A5 true JP2009536522A5 (https=) | 2009-11-26 |
| JP5179474B2 JP5179474B2 (ja) | 2013-04-10 |
Family
ID=37635851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009509467A Active JP5179474B2 (ja) | 2006-05-09 | 2007-05-09 | 拮抗性抗ヒトｃｄ４０モノクローナル抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8669352B2 (https=) |
| EP (2) | EP1854810A1 (https=) |
| JP (1) | JP5179474B2 (https=) |
| KR (1) | KR101506348B1 (https=) |
| CN (1) | CN101490086B (https=) |
| AR (1) | AR060998A1 (https=) |
| AU (1) | AU2007249031B9 (https=) |
| BR (1) | BRPI0711355A2 (https=) |
| CA (1) | CA2651565A1 (https=) |
| CL (1) | CL2007001335A1 (https=) |
| DK (1) | DK2019840T3 (https=) |
| ES (1) | ES2406163T3 (https=) |
| IL (1) | IL195196A (https=) |
| MX (1) | MX2008014304A (https=) |
| NO (1) | NO20085104L (https=) |
| NZ (1) | NZ572756A (https=) |
| RU (1) | RU2491295C2 (https=) |
| TW (1) | TWI455947B (https=) |
| WO (1) | WO2007129895A2 (https=) |
| ZA (2) | ZA200810381B (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| EP3309168A1 (en) | 2009-08-06 | 2018-04-18 | F. Hoffmann-La Roche AG | Method to improve virus removal in protein purification |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| HUE049849T2 (hu) * | 2010-03-31 | 2020-10-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| TR201909840T4 (tr) | 2011-03-11 | 2019-07-22 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antikorları ve kullanımları. |
| HUE038848T2 (hu) | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| CN105636984A (zh) | 2013-06-13 | 2016-06-01 | 法斯特弗沃德制药有限公司 | 用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合 |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| MX383594B (es) | 2014-08-07 | 2025-03-14 | Daiichi Sankyo Co Ltd | Anticuerpo anti-orai1. |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| CN107810198B (zh) | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| BR112018004296B1 (pt) | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| BR112018006251A2 (pt) | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2018178046A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
| AU2018278051A1 (en) | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| KR20200074993A (ko) | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| JP2021513367A (ja) * | 2018-02-12 | 2021-05-27 | ダイアベーツ−フリー， インコーポレイテッド | 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 |
| JP6861301B2 (ja) | 2018-04-13 | 2021-04-21 | ノバルティス アーゲー | 移植片拒絶の予防に使用するための抗ｃｄ４０抗体 |
| AU2019255781A1 (en) | 2018-04-20 | 2020-10-29 | Lyvgen Biopharma Holdings Limited | Anti-CD40 antibodies and uses thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| CN112996818B (zh) | 2018-09-28 | 2022-06-21 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途 |
| EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
| BR112021009835A2 (pt) | 2018-11-30 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
| US20240254248A1 (en) | 2018-11-30 | 2024-08-01 | Jiangsu Hengrui Medicine Co., Ltd. | Cd40 antibody pharmaceutical composition and use thereof |
| CN113271964A (zh) | 2019-01-11 | 2021-08-17 | 诺华股份有限公司 | 化脓性汗腺炎治疗中使用的抗cd40抗体 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| TWI875757B (zh) | 2019-05-08 | 2025-03-11 | 瑞士商諾華公司 | T1dm和胰島炎治療中使用之抗cd40抗體 |
| CA3148890A1 (en) | 2019-09-11 | 2021-03-18 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023020475A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
| CN120463762A (zh) | 2021-08-26 | 2025-08-12 | 映恩生物科技(上海)有限公司 | 一种甾体化合物及其缀合物 |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20250249278A1 (en) | 2022-04-14 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2026082692A1 (en) * | 2024-10-15 | 2026-04-23 | Les Laboratoires Servier | Antibodies to cd40 and compositions thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| DK0945465T3 (da) * | 1992-07-09 | 2007-01-15 | Novartis Vaccines & Diagnostic | Antagonistiske monoklonale antistoffer mod humant CD40 |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| ATE283925T1 (de) | 1996-07-23 | 2004-12-15 | Tanox Pharma B V | Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann |
| EP0983303B1 (en) * | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
-
2006
- 2006-05-09 EP EP06076028A patent/EP1854810A1/en not_active Withdrawn
-
2007
- 2007-05-09 TW TW096116566A patent/TWI455947B/zh not_active IP Right Cessation
- 2007-05-09 CN CN200780025878.9A patent/CN101490086B/zh active Active
- 2007-05-09 DK DK07747426.0T patent/DK2019840T3/da active
- 2007-05-09 MX MX2008014304A patent/MX2008014304A/es active IP Right Grant
- 2007-05-09 ZA ZA200810381A patent/ZA200810381B/xx unknown
- 2007-05-09 NZ NZ572756A patent/NZ572756A/xx not_active IP Right Cessation
- 2007-05-09 WO PCT/NL2007/050202 patent/WO2007129895A2/en not_active Ceased
- 2007-05-09 KR KR1020087030080A patent/KR101506348B1/ko active Active
- 2007-05-09 JP JP2009509467A patent/JP5179474B2/ja active Active
- 2007-05-09 RU RU2008148303/10A patent/RU2491295C2/ru not_active IP Right Cessation
- 2007-05-09 EP EP07747426A patent/EP2019840B1/en active Active
- 2007-05-09 CL CL2007001335A patent/CL2007001335A1/es unknown
- 2007-05-09 AU AU2007249031A patent/AU2007249031B9/en active Active
- 2007-05-09 AR ARP070102017A patent/AR060998A1/es not_active Application Discontinuation
- 2007-05-09 ES ES07747426T patent/ES2406163T3/es active Active
- 2007-05-09 CA CA002651565A patent/CA2651565A1/en not_active Abandoned
- 2007-05-09 US US11/801,344 patent/US8669352B2/en active Active
- 2007-05-09 BR BRPI0711355-2A patent/BRPI0711355A2/pt not_active IP Right Cessation
-
2008
- 2008-11-10 IL IL195196A patent/IL195196A/en active IP Right Grant
- 2008-12-09 NO NO20085104A patent/NO20085104L/no not_active Application Discontinuation
-
2009
- 2009-12-23 ZA ZA2009/09185A patent/ZA200909185B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536522A5 (https=) | ||
| TWI455947B (zh) | 拮抗性對抗人的ｃｄ４０單株抗體 | |
| JP2020501583A5 (https=) | ||
| Peng et al. | Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody | |
| JP2014530611A5 (https=) | ||
| HRP20250482T1 (hr) | Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe | |
| CN102558355B (zh) | 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法 | |
| WO2007111714A3 (en) | Il-21 antagonists | |
| HRP20151418T1 (hr) | MOLEKULE KOJE SE VEŽU NA ANTIGEN S POVEĆANIM AFINITETOM VEZANJA Fc-RECEPTORA I S DJELOTVORNOM FUNKCIJOM | |
| JP2001517425A5 (https=) | ||
| CN103145834B (zh) | 一种抗体人源化改造方法 | |
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| JP2012514997A5 (https=) | ||
| CN116648462A (zh) | Cd3人源化抗体及其应用 | |
| JP2019523221A5 (https=) | ||
| HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
| JP2009517405A5 (https=) | ||
| JP2021513367A5 (https=) | ||
| JP2010506581A5 (ja) | Ｃｔｌａ−４タンパク質変異体 | |
| JP2019523653A5 (https=) | ||
| JP2015514423A5 (https=) | ||
| RU2018135550A (ru) | Связывающие ilt7 молекулы и способы их применения | |
| JP2016520619A5 (https=) | ||
| TW202112800A (zh) | 抗體純化方法及其組成物 | |
| JP6474524B1 (ja) | 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法 |